Prevalence of smoldering multiple myeloma based on nationwide screening-Reference-Cited by-同舟云学术

Prevalence of smoldering multiple myeloma based on nationwide screening

Published:2023-02 Issue:2 Volume:29 Page:467-472
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Thorsteinsdóttir Sigrún^ORCID,Gíslason Gauti K.^ORCID,Aspelund Thor^ORCID,Rögnvaldsson Sæmundur,Óskarsson Jón Þórir^ORCID,Sigurðardóttir Guðrún Á,Þórðardóttir Ásdís R.,Viðarsson Brynjar,Önundarson Páll T.,Agnarsson Bjarni A.,Sigurðardóttir Margrét,Þorsteinsdóttir Ingunn,Ólafsson Ísleifur,Eyþórsson Elías,Jónsson Ásbjörn,Berlanga Oscar,Hultcrantz Malin,Durie Brian G. M.,Löve Thorvardur J.,Harding Stephen,Landgren Ola^ORCID,Kristinsson Sigurður Y.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02183-6.pdf

Reference33 articles.

1. Kyle, R. A. & Greipp, P. R. Smoldering multiple myeloma. N. Engl. J. Med. 302, 1347–1349 (1980).

2. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014).

3. Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007).

4. Kristinsson, S. Y., Holmberg, E. & Blimark, C. Treatment for high-risk smoldering myeloma. N. Engl. J. Med. 369, 1762–1763 (2013).

5. Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4, 1221–1227 (2018).

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review;The Oncologist;2024-09-05

2. Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma;2024-09-04

3. Clinical significance of FLC tests in patients without other evidence of hematologic disorder;Clinical and Experimental Medicine;2024-08-24

4. How to Identify and Manage High-Risk Smoldering Multiple Myeloma;Current Oncology Reports;2024-08-23

5. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions;Pharmaceuticals;2024-07-06